Veliflapon sodium

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 531567

CAS#: 128253-31-6 (acid),

Description: Veliflapon, also known as BAY X 1005 and DG-031, is a leukotriene synthesis inhibitor. BAY x 1005 attenuates atherosclerosis in apoE/LDLR - double knockout mice. BAY-X1005 is a 5-lipoxygenase activating protein (FLAP) inhibitor. BAY-X1005 inhibits the synthesis of leukotrienes B4 and C4 in animal models and it inhibits synthesis of leukotriene B4 in A23187-stimulated leukocytes (IC50 values are 0.026, 0.039 and 0.22 μM for rat, mice and human leukocytes respectively).


Chemical Structure

img
Veliflapon sodium
CAS# 128253-31-6 (acid),

Theoretical Analysis

MedKoo Cat#: 531567
Name: Veliflapon sodium
CAS#: 128253-31-6 (acid),
Chemical Formula: C23H22NNaO3
Exact Mass: 361.17
Molecular Weight: 383.423
Elemental Analysis: C, 72.05; H, 5.78; N, 3.65; Na, 6.00; O, 12.52

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Related CAS #: 128253-31-6 (acid)    

Synonym: BAY-X1005; BAYX1005; BAY X1005; DG-031; DG 031; DG031; Veliflapon; Veliflapon sodium;

IUPAC/Chemical Name: sodium (2R)-2-cyclopentyl-2-[4-(quinolin-2-ylmethoxy)phenyl]acetate

InChi Key: CSKPYCISCFHTLT-VZYDHVRKSA-M

InChi Code: InChI=1S/C23H23NO3.Na/c25-23(26)22(17-6-1-2-7-17)18-10-13-20(14-11-18)27-15-19-12-9-16-5-3-4-8-21(16)24-19;/h3-5,8-14,17,22H,1-2,6-7,15H2,(H,25,26);/q;+1/p-1/t22-;/m1./s1

SMILES Code: O=C([O-])[C@H](C1CCCC1)C2=CC=C(OCC3=NC4=CC=CC=C4C=C3)C=C2.[Na+]

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 383.42 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Roger P, Gascard JP, Bara J, de Montpreville VT, Brink C. MUC5AC mucin release from human airways in vitro: effects of indomethacin and Bay X1005. Mediators Inflamm. 2001 Feb;10(1):33-6. PubMed PMID: 11324902; PubMed Central PMCID: PMC1781691.

2: Nagai H, Takeda H, Uno T, Tanaka H, Matsuo A. Effect of a novel leukotoriene synthesis inhibitor, BAY x1005, on the antigen-and LPS-induced airway hyperresponsiveness in guinea pigs. Prostaglandins. 1996 Feb;51(2):139-48. PubMed PMID: 8711135.

3: Rossoni G, Sala A, Berti F, Testa T, Buccellati C, Molta C, Muller-Peddinghaus R, Maclouf J, Folco GC. Myocardial protection by the leukotriene synthesis inhibitor BAY X1005: importance of transcellular biosynthesis of cysteinyl-leukotrienes. J Pharmacol Exp Ther. 1996 Jan;276(1):335-41. PubMed PMID: 8558451.

4: Hatzelmann A, Goossens J, Fruchtmann R, Mohrs KH, Raddatz S, Müller-Peddinghaus R. Inversely-correlated inhibition of human 5-lipoxygenase activity by BAY X1005 and other quinoline derivatives in intact cells and a cell-free system--implications for the function of 5-lipoxygenase activating protein. Biochem Pharmacol. 1994 Jun 15;47(12):2259-68. PubMed PMID: 8031320.

5: Gardiner PJ, Cuthbert NJ, Francis HP, Fitzgerald MF, Thompson AM, Carpenter TG, Patel UP, Newton BB, Mohrs K, Müller-Peddinghaus R, et al. Inhibition of antigen-induced contraction of guinea-pig airways by a leukotriene synthesis inhibitor, BAY x1005. Eur J Pharmacol. 1994 Jun 2;258(1-2):95-102. PubMed PMID: 7925604.

6: Gorenne I, Labat C, Gascard JP, Norel X, Müller-Peddinghaus R, Mohrs KH, Taylor WA, Gardiner PJ, Brink C. (R)-2-[4-(quinolin-2-yl-methoxy)phenyl]-2-cyclopentyl] acetic acid (BAY x1005), a potent leukotriene synthesis inhibitor: effects on anti-IgE challenge in human airways. J Pharmacol Exp Ther. 1994 Feb;268(2):868-72. PubMed PMID: 8114000.

7: Hatzelmann A, Fruchtmann R, Mohrs KH, Raddatz S, Matzke M, Pleiss U, Keldenich J, Müller-Peddinghaus R. Mode of action of the leukotriene synthesis (FLAP) inhibitor BAY X1005. Implications for biological regulation of 5-lipoxygenase. Adv Prostaglandin Thromboxane Leukot Res. 1994;22:23-31. Review. PubMed PMID: 7771337.

8: Müller-Peddinghaus R, Kohlsdorfer C, Theisen-Popp P, Fruchtmann R, Perzborn E, Beckermann B, Bühner K, Ahr HJ, Mohrs KH. BAY X1005, a new inhibitor of leukotriene synthesis: in vivo inflammation pharmacology and pharmacokinetics. J Pharmacol Exp Ther. 1993 Oct;267(1):51-7. PubMed PMID: 8229782.

9: Müller-Peddinghaus R, Fruchtmann R, Ahr HJ, Beckermann B, Bühner K, Fugmann B, Junge B, Matzke M, Kohlsdorfer C, Raddatz S, et al. BAY X1005, a new selective inhibitor of leukotriene synthesis: pharmacology and pharmacokinetics. J Lipid Mediat. 1993 Mar-Apr;6(1-3):245-8. PubMed PMID: 8395246.

10: Fruchtmann R, Mohrs KH, Hatzelmann A, Raddatz S, Fugmann B, Junge B, Horstmann H, Müller-Peddinghaus R. In vitro pharmacology of BAY X1005, a new inhibitor of leukotriene synthesis. Agents Actions. 1993 Mar;38(3-4):188-95. PubMed PMID: 8213345.